progressive supranuclear palsy
Information
- Disease name
- progressive supranuclear palsy
- Disease ID
- DOID:678
- Description
- "A movement disease that is characterized by serious and progressive problems with control of gait and balance, along with complex eye movement and thinking problems. It involves gradual deterioration and death of specific volumes of the brain." [url:http\://en.wikipedia.org/wiki/Progressive_supranuclear_palsy, url:http\://www.ninds.nih.gov/disorders/psp/psp.htm]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| MAPT | 17 | 45,894,554 | 46,028,334 | 16 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06209515 | Active, not recruiting | Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study | January 1, 2022 | December 31, 2027 | |
| NCT01804452 | Active, not recruiting | 4 Repeat Tauopathy Neuroimaging Initiative | January 2014 | December 2024 | |
| NCT04658199 | Active, not recruiting | Phase 1 | A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | November 16, 2020 | March 30, 2027 |
| NCT04993768 | Active, not recruiting | Phase 2 | A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) | October 15, 2021 | December 31, 2023 |
| NCT04008355 | Active, not recruiting | Phase 2 | A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP | June 22, 2020 | July 1, 2024 |
| NCT00431301 | Completed | Risk Factors for Progressive Supranuclear Palsy (PSP) | August 2006 | June 2013 | |
| NCT00465790 | Completed | Research of Biomarkers in Parkinson Disease | October 2007 | June 2012 | |
| NCT00532571 | Completed | Phase 2/Phase 3 | Effects of Coenzyme Q10 in PSP and CBD | January 2004 | September 2005 |
| NCT00605930 | Completed | N/A | A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. | April 2004 | December 2009 |
| NCT05187546 | Completed | Phase 1 | Test-retest Study With [18F]PI-2620 in PSP-RS and NDC | March 10, 2022 | March 5, 2024 |
| NCT00703677 | Completed | Phase 1/Phase 2 | A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration | September 2008 | January 2010 |
| NCT01049399 | Completed | N/A | Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy | December 2009 | November 2011 |
| NCT01056965 | Completed | Phase 1 | Davunetide (AL-108) in Predicted Tauopathies - Pilot Study | January 2010 | December 2012 |
| NCT01110720 | Completed | Phase 2/Phase 3 | Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy | October 2010 | December 2012 |
| NCT01174771 | Completed | Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration | October 2008 | February 2012 | |
| NCT05067192 | Completed | Optimization of Morphomer-based Alpha-synuclein PET Tracers | July 15, 2021 | September 1, 2021 | |
| NCT01348061 | Completed | Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls | July 2011 | July 2013 | |
| NCT01353183 | Completed | N/A | Analysis of the Enteric Nervous System Using Colonic Biopsies | November 2010 | November 2012 |
| NCT01537549 | Completed | Phase 1/Phase 2 | Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy | September 14, 2010 | April 7, 2015 |
| NCT01563276 | Completed | Postural Instability in Progressive Supranuclear Palsy | December 2011 | May 10, 2013 | |
| NCT01668407 | Completed | N/A | Robot Walking Rehabilitation in Parkinson's Disease | March 30, 2012 | March 31, 2016 |
| NCT04925622 | Completed | Complex Eye Movements in Parkinson's Disease and Related Movement Disorders | January 4, 2021 | April 15, 2022 | |
| NCT02109393 | Completed | N/A | Rehabilitation in Patients With Progressive Supranuclear Palsy | April 2014 | December 2015 |
| NCT04786158 | Completed | Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) | December 1, 2018 | July 1, 2020 | |
| NCT02167594 | Completed | Phase 1 | Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers | August 12, 2014 | July 11, 2016 |
| NCT04715750 | Completed | Phase 1 | Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity | November 12, 2020 | October 26, 2022 |
| NCT02214862 | Completed | Early Phase 1 | 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism | March 2013 | February 2016 |
| NCT02236832 | Completed | N/A | Study of the Neural Basis of Analogical Reasoning | February 2015 | February 2021 |
| NCT02422485 | Completed | Phase 1 | A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy | April 2015 | December 2019 |
| NCT02460094 | Completed | Phase 1 | Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy | October 2, 2015 | October 19, 2016 |
| NCT02460731 | Completed | Phase 1 | Young Plasma Transfusions for Progressive Supranuclear Palsy | May 2015 | December 2019 |
| NCT02494024 | Completed | Phase 1 | Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy | July 2015 | August 2016 |
| NCT04655079 | Completed | N/A | Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) in Progressive Supranuclear Palsy (PSP) (STIM-PSP) | February 1, 2021 | May 11, 2022 |
| NCT02734485 | Completed | N/A | Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy | October 2013 | September 2014 |
| NCT02761707 | Completed | Biomarkers in Neural Disorders | June 2016 | July 16, 2019 | |
| NCT04237948 | Completed | N/A | tDCS Plus Physical Therapy for Progressive Supranuclear Palsy | January 1, 2018 | December 15, 2019 |
| NCT04222218 | Completed | N/A | Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy | June 1, 2017 | November 15, 2019 |
| NCT04185415 | Completed | Phase 1 | A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) | December 3, 2019 | November 17, 2021 |
| NCT04184063 | Completed | Phase 2 | Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) | September 16, 2019 | June 30, 2021 |
| NCT03058965 | Completed | Early Phase 1 | Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain | November 29, 2016 | May 11, 2018 |
| NCT03080051 | Completed | Early Phase 1 | Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain | August 2016 | March 6, 2017 |
| NCT04096651 | Completed | N/A | Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy | September 28, 2015 | July 12, 2018 |
| NCT03926702 | Completed | Early Phase 1 | Tau Imaging With JNJ067 | June 18, 2019 | January 6, 2021 |
| NCT03625128 | Completed | Early Phase 1 | 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls | January 2, 2018 | December 3, 2018 |
| NCT03452956 | Completed | Cognitive Impairement In Frontotemporal Dementia | July 1, 2003 | July 15, 2020 | |
| NCT03478124 | Completed | Neuropsychological Evaluation for Early Diagnosis of PSP | January 1, 2016 | March 2, 2018 | |
| NCT03552484 | Completed | N/A | In-Home Care for Patients With PSP and Related Disorders | May 30, 2018 | December 31, 2020 |
| NCT03545789 | Completed | Phase 1 | Phase 1 Test-retest Evaluation of [18F]MNI-958 PET | March 12, 2018 | February 6, 2020 |
| NCT00005903 | Completed | Phase 2 | Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy | June 2000 | May 2005 |
| NCT00328874 | Completed | Phase 2 | Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy | May 2006 | February 2007 |
| NCT00382824 | Completed | N/A | Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) | September 2006 | January 2015 |
| NCT00385710 | Completed | Phase 2 | Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) | November 2006 | July 2010 |
| NCT06355531 | Not yet recruiting | Phase 2 | A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) | April 2024 | November 2026 |
| NCT06155942 | Not yet recruiting | N/A | Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes | January 15, 2024 | January 15, 2028 |
| NCT06162013 | Not yet recruiting | Phase 2 | The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism | January 2024 | December 2028 |
| NCT06174948 | Not yet recruiting | N/A | The Use of the CUE1 in People With Parkinson's Disease and Related Disorders | March 2024 | December 2025 |
| NCT03924414 | Recruiting | Phase 4 | Trial of Parkinson's And Zoledronic Acid | November 15, 2019 | October 1, 2026 |
| NCT02194816 | Recruiting | Modifiable Variables in Parkinsonism (MVP) | September 2012 | December 2030 | |
| NCT04753320 | Recruiting | Remote Monitoring in Progressive Supranuclear Palsy (PSP) | May 5, 2021 | December 2024 | |
| NCT02114242 | Recruiting | Biomarkers in Parkinsonian Syndromes | December 16, 2013 | December 16, 2025 | |
| NCT05005819 | Recruiting | Phase 1 | Evaluation of [18F]APN-1607 as a PET Biomarker | May 25, 2021 | June 1, 2024 |
| NCT05139342 | Recruiting | N/A | Evaluation of the Efficacy of a Two-week EMST on Dysphagia in Parkinsonian Patients | November 15, 2021 | December 31, 2023 |
| NCT05222386 | Recruiting | N/A | Community Outreach for Palliative Engagement -- Parkinson Disease | April 26, 2022 | August 31, 2026 |
| NCT05459753 | Recruiting | N/A | Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL) | March 1, 2022 | June 30, 2026 |
| NCT05501431 | Recruiting | Personalized Parkinson Project PSP Cohort | May 1, 2021 | June 2024 | |
| NCT05579301 | Recruiting | Study of Comprehensive ANd Multimodal Marker-based Cohort of Progressive Supranuclear Palsy(PSP) | December 19, 2021 | February 28, 2025 | |
| NCT05638477 | Recruiting | N/A | Unstructured Eye Tracking as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders | December 1, 2022 | August 15, 2024 |
| NCT05819658 | Recruiting | Phase 2 | GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) | June 14, 2023 | May 31, 2024 |
| NCT05889260 | Recruiting | Speech Accessibility Project | March 15, 2023 | May 31, 2024 | |
| NCT05913687 | Recruiting | Automated Imaging Differentiation of Parkinsonism | July 22, 2021 | March 31, 2026 | |
| NCT05956834 | Recruiting | A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes | July 28, 2023 | December 30, 2026 | |
| NCT06122662 | Recruiting | Phase 3 | AMX0035 and Progressive Supranuclear Palsy | December 21, 2023 | May 31, 2027 |
| NCT06235775 | Recruiting | Phase 2 | Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 | December 12, 2023 | July 30, 2025 |
| NCT06203106 | Recruiting | NYSCF Scientific Discovery Biobank | November 10, 2022 | November 10, 2045 | |
| NCT03638505 | Recruiting | Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy | July 4, 2019 | July 2026 | |
| NCT03872102 | Recruiting | Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging | March 28, 2019 | August 2024 | |
| NCT03225144 | Recruiting | Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia | October 11, 2017 | October 30, 2025 | |
| NCT03174938 | Recruiting | N/A | The Swedish BioFINDER 2 Study | May 15, 2017 | December 31, 2028 |
| NCT02994719 | Recruiting | Gait Analysis in Neurological Disease | March 1, 2016 | June 20, 2025 | |
| NCT02795052 | Recruiting | N/A | Neurologic Stem Cell Treatment Study | June 2016 | July 31, 2026 |
| NCT04472130 | Recruiting | Neurodegenerative Diseases Registry | October 9, 2019 | August 2024 | |
| NCT04518059 | Recruiting | Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism | March 12, 2019 | May 31, 2024 | |
| NCT04608604 | Recruiting | N/A | Mobility in Atypical Parkinsonism: a Trial of Physiotherapy | February 1, 2021 | November 1, 2024 |
| NCT02605785 | Recruiting | N/A | A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy | November 2015 | November 2025 |
| NCT04691635 | Recruiting | The MOTIVE-PSP Initiative (Progressive Supranuclear Palsy) | January 1, 2022 | January 2025 | |
| NCT04706234 | Recruiting | Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies | September 1, 2017 | July 31, 2024 | |
| NCT00211224 | Terminated | Phase 3 | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) | April 2000 | November 2004 |
| NCT01187888 | Terminated | Phase 3 | Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy | January 2010 | June 2012 |
| NCT02985879 | Terminated | Phase 2 | A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) | December 12, 2016 | November 20, 2019 |
| NCT01815281 | Terminated | N/A | Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease and Progressive Supranuclear Palsy. | July 2013 | April 2015 |
| NCT04367116 | Terminated | N/A | The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy | July 1, 2021 | December 27, 2023 |
| NCT02445469 | Terminated | N/A | Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Syndromes | December 2012 | December 2016 |
| NCT01824121 | Unknown status | Phase 1/Phase 2 | Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism | December 2012 | December 2014 |
| NCT04937530 | Unknown status | Phase 2 | RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY | June 23, 2021 | August 30, 2022 |
| NCT04541836 | Unknown status | Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy | June 15, 2020 | December 31, 2023 | |
| NCT00522015 | Unknown status | Phase 2 | Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy | February 2008 | February 2010 |
| NCT00653783 | Unknown status | Diagnostic and Prognostic Biomarkers in Parkinson Disease | August 2007 | ||
| NCT04734379 | Unknown status | Phase 2 | Rho Kinase (ROCK) Inhibitor in Tauopathies - 1 | January 22, 2021 | November 30, 2023 |
| NCT04139551 | Unknown status | Oxford Study of Quantification in Parkinsonism | October 2016 | December 2023 | |
| NCT05260151 | Unknown status | Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases | November 18, 2020 | December 31, 2022 | |
| NCT02964637 | Unknown status | Diagnosing Frontotemporal Lobar Degeneration | August 2015 | December 2019 | |
| NCT04253132 | Unknown status | Phase 1/Phase 2 | Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks | January 1, 2021 | December 31, 2022 |
| NCT03269201 | Unknown status | Brain Network Activation in Patients With Movement Disorders | March 1, 2019 | September 15, 2022 | |
| NCT03446807 | Withdrawn | Phase 2 | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | December 2021 | July 1, 2023 |
| NCT04883229 | Withdrawn | N/A | tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study | July 1, 2022 | November 30, 2023 |
- Disase is a (Disease Ontology)
- DOID:480
- Cross Reference ID (Disease Ontology)
- GARD:7471
- Cross Reference ID (Disease Ontology)
- ICD10CM:G23.1
- Cross Reference ID (Disease Ontology)
- MESH:D013494
- Cross Reference ID (Disease Ontology)
- MIM:601104
- Cross Reference ID (Disease Ontology)
- MIM:609454
- Cross Reference ID (Disease Ontology)
- MIM:610898
- Cross Reference ID (Disease Ontology)
- NCI:C85028
- Cross Reference ID (Disease Ontology)
- ORDO:683
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:192975003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0038868
- Exact Synonym (Disease Ontology)
- progressive supranuclear ophthalmoplegia
- Exact Synonym (Disease Ontology)
- Steele-Richardson-Olszewski syndrome
- OrphaNumber from OrphaNet (Orphanet)
- 683